Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2411)	12/28/2000 10:53:54 AM
From: rkrw	Read Replies (1) \| Respond to of 52153

Peter, What risks do you attach to the FDA's comments regarding muscle toxicity and what % of trial participants are seeing this side effect? How effective is daptomycin at low doses? Will this side effect curtail high dose usage and does this impact the overall market opportunity? Is this a potential stumbling block or much ado about nothing? (To give credit where credit is due, Rick mentioned this side effect two years ago). Jay Silverman at RS has some heavy sales projections for dapto. I've heard that LLY did retain a significant royalty stake. RKRW